HCW Biologics Inc. Common Stock HCWB

HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.

HCWB hizo una agrupación de acciones (split inverso) de 1:6 el 30 de junio de 2026: cada 6 acciones se juntaron en una. Bajó la cantidad de acciones y subió su precio, pero no el valor total de la inversión.

• GlobeNewswire Inc. 8 sept

  HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells

  HCW Biologics Inc. announced an exclusive distribution agreement with Akron Biotech to commercialize HCW11-006, a multi-cytokine fusion molecule designed to improve CAR-T cell manufacturing. The reagent demonstrated superior performance in preclinical studies, generating more potent and longer-lasting CAR-T cells while potentially reducing production costs compared to conventional methods.

  

• GlobeNewswire Inc. 25 ago

  HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells

  HCW Biologics announced that its TGF-β trap and IL-15 fusion moiety promotes expansion of CD8+ T cells and NK cells, demonstrating clinical benefit in cancer patients and activity against HIV-1 and bronchopulmonary dysplasia. The company has incorporated this discovery into second-generation T Cell Engager (HCW11-018b) and Immune Checkpoint Inhibitor (HCW11-040) programs, with both candidates at IND-enabling stage and clinical studies planned for 2027.